Podcast appearances and mentions of Johnson Johnson

Ever stared at a toothpaste tube and wondered if it could take you higher? In episode 18 of Rabbit Hole, Billy Merritt and the BIT Comedy players tumble from dental conspiracies and Norwegian stop-motion cartoons to hoarding hotel soaps, prank-calling Captain Crunch, and even a pirate gang in juvie. Along the way, fluoride turns into Flo Rida, the Soggies declare war, and toothpaste becomes the most questionable substance at the Cannabis Cup. It's improv chaos at its finest: absurd connections, quick character swaps, and the kind of storytelling detours only this ensemble could conjure. From corporate “green peas” to Plato's cave, with a bit of toothpaste smoke in the air, this Rabbit Hole has it all.

O BANZAcast é a sua dose semanal de chapação!Patrocínio: Encontre os melhores substratos para o seu cultivo na Dedo Verde Substratos! Colheitas mais fartas, com qualidade e simplicidade, você encontra na https://dedoverdesubstratos.comEntre na nossa loja e compre os produtos exclusivos do BANZAcast!https://umapenca.com/banza/Desde 2019, com novos episódios onde falamos do mundo na perspectiva do maconheiro.Muita fumaça, risada e informação aqui no nosso podcast.Conheça nossa página de apoio, no https://apoia.se/banzaoficialTodos os nossos links: https://linktr.ee/banzaoficialDisponível no seu agregador de podcast preferido.

In this lecture, we explore the ideas of Peter Drucker, often called the father of modern management. Drucker argued that the true purpose of business is to create a customer, and that innovation and responsibility are at the heart of management practice. We discuss his influence on concepts such as management by objectives, the rise of knowledge workers, and the ethical role of corporations in society. With examples from Intel, Apple, and Johnson & Johnson, the episode highlights how Drucker's broad and pragmatic vision continues to shape how organizations think about strategy, purpose, and responsibility in a turbulent world.

In this episode of Investor Connect, Hall Martin speaks with Rachna Dayal, a global health biotech and venture investment expert, founder of Sugati Ventures.  Rachna shares her transition from corporate roles at Johnson & Johnson and Philips to founding and running a venture fund focused on transformative health tech startups. She talks about the major differences between working in large corporations and managing a small VC fund, emphasizing the importance of flexibility and addressing high unmet needs in healthcare through innovative solutions in medical devices and AI-enabled platforms.  Rachna highlights her investment thesis around consumer-first, purpose-led brands, particularly focusing on life-saving devices and enhancing quality of life, and discusses the crucial role of founder-market fit and diverse backgrounds in fostering innovation in the healthcare space. She also touches on current trends such as the rise of AI in healthcare and the impact of economic conditions on venture capital, offering advice for new investors and emphasizing the need for perseverance during tough times in the investment landscape.  Visit Sugati Ventures at Reach out to at   _______________________________________________________ For more episodes from Investor Connect, please visit the site at:    Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

What if the real secret to exceptional leadership isn't control, charisma, or even performance—but generosity? Could the “soft stuff” like listening, empathy, and vulnerability truly drive the hardest results in business? In this episode of the Delighted Customers podcast, I dig into that very question with Joe Davis, legendary former Senior Partner at Boston Consulting Group, co-founder of BCG's Washington D.C. office, and author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain”. Joe shares his own journey from traditional, results-driven leadership to a generous, people-centered model—and why unlocking your team's full human potential just might be the most powerful business move you can make. We explore how the traits of generosity drive not only team happiness and loyalty, but also real bottom-line outcomes, making this conversation essential listening for leaders and aspiring leaders at every level. Why should you tune in to this episode? Joe has four decades of hands-on experience innovating in both the private and public sectors, founding major business initiatives within BCG, and working closely with Fortune 500 C-suite leaders. He distills this wisdom into practical strategies—whether you're leading a team of three or a global enterprise of 100,000. His stories from the front lines of consulting, combined with actionable steps for building trust and humanity in the workplace, will change the way you think about leadership forever. Here are three compelling questions Joe answers on the show: Why should organizations and their C-suite invest in “generous leadership” when they're held accountable for hard business outcomes, not just a healthy culture? What are the seven key traits that separate good leaders from exceptional, generous leaders—and how do they play out in real-world scenarios? How can listening, vulnerability, and small acts of recognition dramatically improve your team's performance and engagement? Listen now and subscribe to the Delighted Customers podcast on Apple Podcasts and Spotify! You'll find this episode—and every episode—on all your favorite podcast platforms. If you find value in these conversations, please leave a review and share with a friend or colleague who wants to rethink what great leadership really looks like. Meet Joe Davis Joe Davis is a veteran senior partner at Boston Consulting Group (BCG), where he spent 37 years shaping strategy, developing talent, and transforming organizations at the highest level. Joe co-founded BCG's Washington D.C. office and launched the firm's North American Public Sector business, as well as leading BCG North America. Passionate about advancing equity and inclusion, he also founded and chaired BCG's Center for Inclusion and Equity. Joe is a Harvard Business School graduate and has been at the forefront of helping organizations evolve from top-down, authoritarian structures to cultures of trust, inclusion, and generosity. His experience spans advising CEOs of major corporations to hands-on coaching with emerging leaders. He is the author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain,” a groundbreaking book that reimagines the connection between caring leadership and delivering results. Joe is currently an advisor and coach to BCG's rising partners, teaching them how to inspire, motivate, and build lasting client relationships. You can reach Joe and learn more about his work via his LinkedIn profile or his website at joedavis.com. Show References and Resources “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain” by Joe Davis Amazon Link Joe Davis on LinkedIn: https://www.linkedin.com/in/joe-davis-bcg/ Joe's personal website: https://joedavis.com Harvard Business School: https://www.hbs.edu Boston Consulting Group (BCG): https://www.bcg.com Michigan State University's Trust and Leadership Education: https://broad.msu.edu CEO Joaquin Duato, Johnson & Johnson: https://www.jnj.com/leadership/joaquin-duato Scott Kirby, CEO of United Airlines: https://www.united.com/ual/en/us/fly/company/about/leadership.html Sheila Bair, former FDIC chair: https://www.fdic.gov/about/leadership/sheila-bair/ Thank you for listening to the Delighted Customers podcast!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

“Walk the talk is the most powerful way to build trust.” “Beauty grooming didn't exist—it was a new word to reflect a new purpose.”  “People didn't see themselves in the beauty industry until they started to look in the mirror.” “Recognition isn't just celebration—it's about noticing the mindset, not only the results.” Previously Hideo was Country Manager, Beauty Care Japan & Korea at Henkel; General Manager of several divisions at L'Oreal in Japan & Taiwan; Product Manager at Johnson & Johnson. He has a BA from Meiji University and an MBA form Thunderbird School Of Global Management. Hideo leads with a transformational mindset rooted in purpose, clarity, and genuine human connection. His leadership approach centers on revitalizing legacy organizations by redefining their identity and embedding a culture of innovation, joy, and self-belief. Across five successful turnaround cases in his career, Hideo discovered that real change begins not with strategy, but with a compelling purpose and vision. At Schick Japan, he introduced the idea of “beauty grooming” as a new brand identity—transforming shaving from a commodity into a value-rich, emotionally resonant experience. This pivot reimagined the business from a transactional model reliant on discounts to one driven by brand value and aspiration. To implement this shift, Hideo engaged in one-on-one conversations with all 110 employees within the first two months. This individual engagement served a dual purpose: to build trust and to carefully test and refine his ideas based on team feedback before rolling them out. Through these personal interactions, he unearthed stories—like a senior employee's joyful transformation using hair color—that became powerful internal case studies. By elevating that individual as a “beauty ambassador,” Hideo catalyzed a grassroots movement that encouraged self-care, pride, and alignment with the new company purpose. Recognizing that vision needs more than words to take hold, Hideo invested heavily in visual and cultural transformation. A dramatic office renovation served as a physical manifestation of the company's new identity. The modern, light-filled space brought the abstract idea of “joyful beauty grooming” to life and signaled serious commitment to change. This, paired with the creation of an on-site innovation studio, reinforced the values of creativity and forward momentum. Hideo believes in “walking the talk” as the cornerstone of building trust. By visibly following through on promises—whether it's office renovation, launching new products, or creating a culture of recognition—he demonstrates integrity in action. He instituted a structured recognition culture, teaching managers to appreciate not only results but also processes and mindset. He emphasizes the importance of linking every achievement back to the company's core values, reinforcing a culture that is both consistent and inspiring. His leadership style is characterized by balance—between top-down direction and bottom-up input, between Western urgency and Japanese reflection, and between innovation and cultural sensitivity. He tailors his approach depending on readiness, starting with senior leadership, cascading through middle management, and then to staff. He nurtures psychological safety by decoupling innovation from punishment, encouraging experimentation while accepting failure as part of growth. For Hideo, transformation is not a single event but a step-by-step evolution: purpose and vision, then strategy, followed by organizational alignment, early wins, recognition and celebration, and finally, values reinforcement and cultural embedding.His ability to translate abstract concepts into tangible systems and environments, while maintaining an authentic and inclusive leadership presence, has made him a standout figure in modern corporate leadership in Japan.

Wells Fargo Senior Economist Sarah House leads "The Jackson 5" analysis of key economic indicators ahead of the Fed symposium. Wedbush's Matt Bryson explains his Nvidia price target hike this week ahead of earnings. Brooke May from Evans May Wealth charts the market's next move. Plus, an exclusive look inside one of America's largest biologic drug manufacturing plants as Fujifilm's North Carolina facility prepares to produce drugs for Johnson & Johnson and Regeneron. Tom Rogers, former NBC Cable President and Versant Board senior advisor, breaks down the streaming wars as ESPN launches its new standalone app. 

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Gina Torres, a nurse-turned-medical device sales professional at Johnson & Johnson, to unpack what it really takes to thrive in one of the most competitive fields in healthcare: peripheral vascular and coronary sales. Gina shares her inspiring journey from working multiple nursing jobs to consolidating her career into one life-changing role in medical device sales. She reveals how she broke into the industry, why she chose Shockwave's groundbreaking intravascular lithotripsy technology, and what makes the clinical specialist role such a powerful entry point for both clinicians and driven non-clinicians. From balancing 5 a.m. case starts to late-night procedures, Gina gives a behind-the-scenes look at the unpredictable but rewarding life of a vascular rep. She also breaks down the income potential, the skills that truly separate top performers, and why grit, empathy, and the ability to “get comfortable being uncomfortable” matter more than a clinical background. Whether you're a nurse considering the leap, a bachelor's graduate wondering if you can compete, or an aspiring sales rep curious about cardiovascular devices, this conversation delivers raw insights, career strategies, and real talk about success in medical sales. Connect with Gina: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode, hosts Mark Longo and Dan Passarelli (Market Taker Mentoring) delve into various listener-submitted questions and trading strategies. They talk about a listener's in-depth query on a put calendar trade with Johnson & Johnson and its associated risks, and another listener's covered call strategy dubbed 'Ultra Premium Harvesting.' The hosts also answer inquiries on the use case and risks involved in trading inverse volatility products like SVXY, and discuss the optimal products and strategies for trading precious metals like gold and silver. Additionally, they address a listener's request about visiting the studio and potential local meet-ups.   01:12 Welcome to Options Bootcamp 03:10 Listener Mail Call 03:57 Ben's Epic Treatise on Put Calendars 11:39 Michael K's Ultra Premium Harvesting Strategy 17:00 Exploring Inverse Volatility Products 20:21 Trading Precious Metals 23:21 Listener Annet's Chicago Visit 25:08 Conclusion and Upcoming Episodes  

In this episode, hosts Mark Longo and Dan Passarelli (Market Taker Mentoring) delve into various listener-submitted questions and trading strategies. They talk about a listener's in-depth query on a put calendar trade with Johnson & Johnson and its associated risks, and another listener's covered call strategy dubbed 'Ultra Premium Harvesting.' The hosts also answer inquiries on the use case and risks involved in trading inverse volatility products like SVXY, and discuss the optimal products and strategies for trading precious metals like gold and silver. Additionally, they address a listener's request about visiting the studio and potential local meet-ups.   01:12 Welcome to Options Bootcamp 03:10 Listener Mail Call 03:57 Ben's Epic Treatise on Put Calendars 11:39 Michael K's Ultra Premium Harvesting Strategy 17:00 Exploring Inverse Volatility Products 20:21 Trading Precious Metals 23:21 Listener Annet's Chicago Visit 25:08 Conclusion and Upcoming Episodes  

How can biotech companies stay resilient and competitive when public sector funding becomes unpredictable? In this episode, host James Zanewicz, JD, LLM, RTTP, sits down with Adeyinka “Adey” Pierce-Watkins, MS, PMP—Director of Biodefense and Government Contracting at BDO USA—for a timely conversation on surviving and thriving in today's evolving federal funding landscape. From defense contracts to international partnerships, Adey shares practical guidance for life science leaders aiming to tap into strategic public funding opportunities. In this episode, you'll learn: How to identify and access alternative funding sources—including state, federal, and international opportunities. What biotech organizations need in place to be “government-ready” for grants, contracts, and urgent response funding. Why strategic planning, partnerships, and compliance infrastructure are essential to winning and executing federal awards. Whether you're pursuing BARDA grants, entering international consortia, or rethinking your risk exposure, this episode offers actionable insights to help biotech innovators chart a smarter path forward. Links: Connect with Adey Pierce, MS, PMP, and check out BDO USA. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about the Cancer Prevention & Research Institute of Texas, TEDCO, and the California Institute for Regenerative Medicine. Learn more about Flagship Pioneering, Andreessen Horowitz, Novartis, Johnson & Johnson, and Roche. Learn more about HERA, Horizon Europe, AMED, and A*STAR. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of the People of Packaging podcast, host Adam Peek sits down with Michael Houston, President & CEO of Future Blue Group and Co-founder of Shower Pouch, for an insightful conversation that delves into his extensive career in packaging and his passion for innovative, sustainable solutions.Michael's Journey: From Corporate Giants to Entrepreneurial VenturesMichael shares his impressive career trajectory, starting with his time at major CPG companies like Procter & Gamble and Johnson & Johnson, where he gained invaluable experience in packaging R&D and operations. He later transitioned to companies like Beachbody, where he began to focus on helping smaller businesses navigate the complexities of product development and market entry. His experience also includes roles at Unilever, working with beauty brands like Murad, Dermalogica, and Kate Somerville, and contributing to the Honest Company's IPO. This rich background has fueled his current entrepreneurial pursuits.Introducing Shower Pouch: The On-the-Go Hygiene SolutionA significant portion of the discussion revolves around Shower Pouch, a product born from a personal problem statement. Michael recounts how his father, serving in Afghanistan, highlighted the need for a better hygiene solution than just baby wipes. Collaborating with his business partner, Omar Jimenez (a talented chemist), they developed Shower Pouch – a high-quality, durable, and highly absorbent non-woven wipe designed to clean an entire body with just one product. The conversation touches on:* The Problem: Addressing the need for convenient and effective hygiene solutions for military personnel, hospital patients, and even active individuals on the go.* The Innovation: The use of a specialized non-woven material that is highly absorbent and durable, allowing for efficient cleaning.* Sustainability Focus: Shower Pouch is designed as a durable good, emphasizing reusability and minimizing waste. The packaging even suggests washing and repurposing the wipes.* Convenience: The product can be used on its own or heated for a more comfortable experience.* Availability: Shower Pouch is available on Amazon Prime and through their website, theshowerpouch.com.Future Blue Group: Driving Sustainable Packaging for CPG BrandsMichael's consultancy, Future Blue Group, leverages his deep industry knowledge to assist CPG brands in various aspects of packaging. The discussion highlights:* Key Areas of Focus: Future Blue Group helps brands with cutting-edge technical packaging solutions, cost reduction, enhancing packaging aesthetics, improving customer experience, integrating sustainability principles, optimizing supply chain operations, and accelerating market entry.* Industry Successes: Michael notes significant success working with brands in the supplement space, where he helps optimize packaging for shelf stability and manufacturability, moving beyond generic stock options. He also finds considerable success in the personal care, masstige, and prestige categories, where he navigates complex material and formulation challenges to ensure both aesthetics and functionality.* The Importance of Data: Michael emphasizes the critical role of data in making informed packaging decisions. He advocates for a scientific, objective approach to sustainability, starting with verifiable data rather than relying on "greenwashing" or gut feelings. This is where tools like Specright.com and Trayak become invaluable.Sustainability in Packaging: A Call for ClarityMichael offers crucial advice for brands tackling sustainability:* Define Your Sustainability: He stresses the importance of clearly defining what sustainability means for your specific brand – whether it's compostability, recyclability, durability, or a combination. A clear definition allows for quantifiable goals and avoids being "all over the place."* Embrace Material Science: Understanding the materials you're working with, their manufacturing processes, and their environmental impact is key to making truly sustainable choices.* Beyond Greenwashing: Move past superficial claims and commit to science-based decisions that genuinely reduce environmental impact, particularly focusing on reducing CO2 emissions.Connect with Michael Houston:* LinkedIn: Michael Houston* Future Blue Group: Find them on LinkedIn* Shower Pouch: theshowerpouch.com* Email: michael.houston@futurebluegroup.com This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.packagingisawesome.com

This Day in Legal History: Medicare and Medicaid Signed into BeingOn July 30, 1965, President Lyndon B. Johnson signed the Social Security Amendments of 1965 into law, creating the Medicare and Medicaid programs. The signing took place at the Truman Library in Independence, Missouri, with former President Harry S. Truman—an early advocate for national health insurance—present and symbolically receiving the first Medicare card. Medicare was designed to provide hospital and medical insurance to Americans aged 65 and older, regardless of income or medical history. Medicaid, created alongside Medicare, offered healthcare assistance to low-income individuals and families.At the time, nearly half of Americans over 65 had no health insurance. The passage of Medicare was a landmark achievement of Johnson's Great Society initiative and built on decades of political struggle over healthcare reform. The legislation amended Title XVIII of the Social Security Act and was strongly opposed by many in the medical establishment and conservative politicians who labeled it as “socialized medicine.” Nevertheless, the program gained rapid popularity and provided immediate relief to millions.Administered by the federal government, Medicare initially had two parts: Part A, covering hospital insurance, and Part B, covering outpatient and physician services. It has since evolved to include prescription drug coverage (Part D) and options for private plans (Medicare Advantage). The law reshaped the American healthcare landscape and established the principle that access to healthcare for seniors was a federal responsibility.The U.S. Senate confirmed Emil Bove, a former lawyer for Donald Trump and senior Justice Department official, to a lifetime seat on the 3rd U.S. Circuit Court of Appeals in a narrow 50-49 vote. Bove faced unified Democratic opposition and criticism from over 900 former DOJ employees, who claimed he undermined the department's integrity. His nomination prompted a Democratic walkout during the Senate Judiciary Committee's vote and drew sharp condemnation from Senate Majority Leader Chuck Schumer.Despite controversy, Republicans praised Bove's background as a federal terrorism prosecutor and his legal work defending Trump in several criminal cases. His confirmation shifts the appellate court's balance back in favor of Republican appointees. Critics cited Bove's alleged directives that defied judicial authority and political interference in a corruption case against New York Mayor Eric Adams. Bove denied wrongdoing in both instances. His confirmation is part of Trump's renewed effort in his second term to reshape the judiciary, following over 230 appointments in his first term. Trump has also nominated another close adviser, Jennifer Mascott, to the same court.Trump lawyer Bove confirmed to US appeals court, overcoming Democratic opposition | ReutersBove Confirmed to Appeals Court After Whistleblowers Emerge (1)A White House crypto task force established by President Trump is set to release a highly anticipated report outlining the administration's policy goals for the digital asset sector. The report, expected Wednesday, will address tokenization, market structure legislation, and a regulatory framework for blockchain-based financial products. Created by executive order shortly after Trump took office in January, the group is led by Bo Hines and includes top officials such as Treasury Secretary Scott Bessent and SEC Chair Paul Atkins.The document is expected to support expanded use of tokenization, which converts traditional assets like stocks and real estate into blockchain-based tokens. The report may call on the SEC to create a framework enabling firms like Coinbase to offer tokenized securities, though specific language remains under wraps. It will also outline the White House's preferences for crypto legislation currently advancing in Congress, including follow-up to the recently passed stablecoin law.Trump has made pro-crypto policies a centerpiece of his administration, reversing many of the enforcement actions taken under President Biden, such as lawsuits against Coinbase and Binance. While the industry sees the report as a roadmap for mainstream integration, concerns remain about conflicts of interest, particularly given Trump's financial ties to crypto ventures and meme coins. The administration has denied any ethical violations.White House set to unveil closely watched crypto policy report | ReutersThe Trump administration has formally requested the release of grand jury transcripts related to Jeffrey Epstein and Ghislaine Maxwell, citing public interest and mounting pressure over the government's handling of the sex trafficking cases. Prosecutors filed late-night motions with U.S. District Judges Richard Berman and Paul Engelmayer, arguing that the sealed testimony should now be disclosed, though the judges had previously asked for stronger legal justification. Grand jury records are typically secret, with limited exceptions for disclosure.Trump said he directed Attorney General Pam Bondi to seek the unsealing after the Justice Department reaffirmed its conclusion that Epstein died by suicide and that there was no list of elite clients—a stance that frustrated some Trump supporters who suspect a cover-up. Epstein died in 2019 before his trial; Maxwell, convicted in 2021, is serving a 20-year sentence and has appealed to the Supreme Court to overturn her conviction.In a related effort, a Florida judge recently denied a separate request to release grand jury records from earlier state investigations into Epstein, ruling they did not meet legal exceptions. Even if the federal judges allow the current transcripts to be unsealed, the documents may not reveal new information, since much of the testimony was covered during Maxwell's trial. The transcripts also wouldn't encompass the full scope of investigative material held by the government.Deputy Attorney General Todd Blanche, a former Trump lawyer, recently met with Maxwell for two days, reportedly seeking any names or evidence she could provide about others potentially involved. Neither Blanche nor Maxwell's attorney has commented in detail on those meetings.Trump administration asks judges to release Epstein, Maxwell grand jury transcripts | ReutersA Massachusetts jury has ordered Johnson & Johnson to pay over $42 million to Paul Lovell, who developed mesothelioma after decades of using the company's talc products. Lovell and his wife sued in 2021, claiming the talc contained asbestos that he unknowingly inhaled, and accused J&J of failing to warn consumers despite knowing the risks. The jury awarded damages for pain, suffering, and medical costs.J&J denied any wrongdoing, calling the verdict “junk science” and saying its products are asbestos-free and safe, with plans to appeal the decision. The company ended U.S. sales of talc-based baby powder in 2020. This case adds to a string of multi-million-dollar verdicts against J&J in talc-related mesothelioma lawsuits, although some have been overturned on appeal.J&J is facing over 63,000 active lawsuits, and possibly up to 100,000 claims in total, most alleging ovarian cancer from talc use. The company's attempts to resolve the claims through bankruptcy have failed in court three times, including a $10 billion settlement proposal rejected in March. The Lovell case is part of ongoing litigation that continues to test J&J's legal strategy and product safety claims.Johnson & Johnson ordered to pay $42M after jury finds talc caused man's cancer | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Today we'll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline?   Our guest today is Dr.  Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine.   References: https://www.nature.com/articles/s41598-024-79918-7   Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Bristol Myers Squibb, GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Bristol Myers Squibb, GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This episode covers: Cardiology This Week: A concise summary of recent studies ICD Indications in primary prevention Drug treatment of cardiac amyloidosis Mythbusters Host: Rick Grobbee Guests: Carlos Aguiar, Gerhard Hindricks, Marianna Fontana Want to watch that episode? Go to: https://esc365.escardio.org/event/1810   Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Gerhard Hindricks Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1810?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Carl Quintanilla and Jim Cramer explored what to make of a second day of bank earnings, led by Bank of America, Goldman Sachs and Morgan Stanley. The chip sector's record run also in the spotlight, led by Nvidia trading at all-time highs. The anchors reacted to comments made by Nvidia CEO Jensen Huang in Beijing about doing business in China. The Producer Price Index for June comes in tamer than expected, showing wholesale inflation unchanged month-on-month. Also in focus: ASML drags chip equipment stocks lower, Johnson & Johnson jumps on earnings, President Trump from trade to your 401(K), crypto legislation vote watch. Squawk on the Street Disclaimer

In this episode explore what makes for effective leadership with host Kyle Forrest and Peter Fasolo, former chief human resources officer at Johnson & Johnson. You'll gain insight into the power of systems thinking, board collaboration, aligning your people agenda with enterprise strategy, and more. Tune in now and learn how to lead with impact in today's dynamic HR landscape.

The title is a joke, but it's funny...and who knows, maybe it'll happen. Biggest brand deal ever? lol.Membership Specials https://swolenormousx.com/membershipsDownload The Swolenormous App https://swolenormousx.com/swolenormousappMERCH - https://papaswolio.com/Watch the full episodes here: https://rumble.com/thedailyswoleSubmit A Question⁠ For The Show: https://swolenormousx.com/apsGet On Papa Swolio's Email List: https://swolenormousx.com/emailDownload The 7 Pillars Ebook: https://swolenormousx.com/7-Pillars-EbookTry A Swolega Class From Inside Swolenormous X: https://www.swolenormousx.com/swolegaGet Your Free $10 In Bitcoin: https://www.swanbitcoin.com/papaswolio/   Questions? Email Us: Support@Swolenormous.com

Kiernan Laughlin is the General Manager and co-creator of Deep Indian Kitchen, a growing CPG brand whose mission is to bring a modern, high-quality Indian food experience to consumers worldwide. Kiernan previously held senior brand management roles at large CPG companies like Johnson & Johnson and Unilever, and he spent his early career in marketing, promotions, and partnership leadership at Gorton's Seafood.Highlights from our conversation include:Core business and leadership lessons from Kiernan's career in multi-stage CPG (1:26)Useful skills Kiernan picked up outside of work that have percolated into his leadership style (5:27)Going from a structured corporate environment to leading an emerging brand (8:01)The challenges and opportunities of building a team through rebranding (11:22)Elements that make a successful relationship between CEO and Founder (19:36)Keeping his team aligned and agile as the company evolves (21:48)Hiring for qualities that go beyond the resume (22:49)How Deep connects their mission to action through their foundation (27:08)Advice for the next generation of CPG leaders (30:13)Visit HowIHire.com for transcripts and more on this episode.Follow Roy Notowitz and Noto Group Executive Search on LinkedIn for updates and featured career opportunities.Subscribe to How I Hire:AppleSpotifyAmazon